AVITA Medical Announces U.S. National Market Launch of RECELL System

The U.S. sales team of Regenerative Tissue Specialists and Clinical Training Specialists that joined AVITA Medical in November 2018 has been trained and fully deployed across the U.S. in support of the nationwide launch of the RECELL System.

KCI Enters Into a Performance-Based Agreement with Highmark for the KCI iOn PROGRESS Remote Therapy Monitoring Program

12/18/18: KCI iOn PROGRESS™ Remote Therapy Monitoring Program aims to improve overall patient experience, lower costs through increased engagement & adherence.

ARANZ Medical Raises NZ$5mil New Equity Financing

ARANZ Medical Silhouette system automates the imaging, measurement and documentation of skin conditions, including chronic wounds.

The MHRA Approves Phase IIa Clinical Trial Application for Tri-Solfen for Venous Leg Ulcers: Product to be Branded as Medi-Solfen

12/17/18: the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its application for a Phase IIa clinical trial of Tri-Solfen® (for human use the product will be branded as Medi-Solfen®) for the treatment of pain during the surgical debridement of venous leg ulcers.

Separate Independent Studies Found PREVENA Therapy Reduced Complications Following Breast Cancer Surgery and Breast Reconstruction

11/12/18: PREVENA™ Incision Management System reduced postsurgical wound complication potential in patients recovering from oncological breast surgery and breast reconstruction, respectively.

AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL System in Treatment of Children with Burn Injuries

10/25/18: Avita Medical reports the clinical study is being conducted in Brisbane, Australia in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital.

Double-Blind Randomized Study Evaluates Continuous Diffusion of Oxygen in Patients with Chronic Wounds

9/28/18:"We are very pleased by the clinical results of these two studies, which continue to support the benefits of the EO2 System as a safe and effective therapeutic option for patients suffering from the devastating effects of unhealed wounds," stated Joe Moffett, President of EO2 Concepts. "I look forward to building on our commercial successes in the U.S., Canada, Europe, and the Middle East and supporting physicians and patients with this effective wound healing therapy."

AVITA Medical Announces Acquisition of Manufacturing Facility to Support Planned U.S. Launch of RECELL Device

“Having direct control over the manufacturing of RECELL will ensure that we have the capacity to meet commercial demand, including the planned U.S. launch and the BARDA procurement, and provide us further control over our production processes and timelines,” said Dr. Michael Perry, Chief Executive Officer. “Acquiring this facility that has a track record of producing RECELL allows us to realize the benefits of inhouse production while maintaining the continuity of proven manufacturing and quality processes and systems.”